VALCYTE 450 MG — DIN 02245777
VALGANCICLOVIR (VALGANCICLOVIR HYDROCHLORIDE) : 450 MG · CHEPLAPHARM ARZNEIMITTEL GMBH · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is VALCYTE?
VALCYTE 450 MG contains VALGANCICLOVIR (VALGANCICLOVIR HYDROCHLORIDE) : 450 MG. It is listed in the Health Canada Drug Product Database under DIN 02245777, held by CHEPLAPHARM ARZNEIMITTEL GMBH, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 19-Jul-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VALCYTE used for?
VALCYTE (valganciclovir hydrochloride, film coated tablets and powder for oral solution) is indicated for adult patients for: The treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). The prevention of cytomegalovirus (CMV) disease in solid organ transplant patients who are at risk.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Valganciclovir cost around the world?
Valganciclovir is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| United States | acquisition | 2 | 25 |
| Australia | ex-manufacturer | 3 | 9 |
| Italy | prezzo al pubblico (classe A) | 4 | 7 |
| Saudi Arabia | public | 7 | 7 |
| South Africa | single exit price | 4 | 4 |
| Bahrain | retail (max) | 3 | 3 |
| Greece | producer price (ex-factory) | 3 | 3 |
| United Kingdom | hospital | 1 | 1 |
| Romania | max producer price | 1 | 1 |
60 pack listings across 28 brand entries and 9 price bases, refreshed 08 Sep 2026. Ranges span every Valganciclovir pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Valganciclovir in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
7 holders have a Canadian DIN containing Valganciclovir, across 9 DINs, of which 6 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AURO PHARMA INC | 2 | 2 | AURO-VALGANCICLOVIR | Sourceable in Canada |
| CHEPLAPHARM ARZNEIMITTEL GMBH | 2 | 2 | VALCYTE | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 1 | 1 | MINT-VALGANCICLOVIR | Sourceable in Canada |
| TEVA CANADA LIMITED | 1 | 1 | TEVA-VALGANCICLOVIR | Sourceable in Canada |
| APOTEX INC | 1 | 0 | APO-VALGANCICLOVIR | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 1 | 0 | MYLAN-VALGANCICLOVIR | No marketed DIN |
| NATCO PHARMA (CANADA) INC | 1 | 0 | NAT-VALGANCICLOVIR | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 450 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Tablets: plastic bottles of 60. Powder for oral solution: carton containing an amber glass bottle with child-resistant plastic screw cap, a bottle adapter and a sealed bag containing 2 oral dispensers. Each bottle contains 12 g of powder for oral solution. When reconstituted, the volume of the solution is 100 mL, providing a minimal usable volume of 88 mL. |
| Storage | 2-8°C (Reconstituted solution shelf-life) |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Valganciclovir |
|---|---|
| ATC code | J05AB14 |
| AHFS class | 08:18.32 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02245777 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2245777 |
| Brand name | VALCYTE |
| Generic / active ingredient | VALGANCICLOVIR (VALGANCICLOVIR HYDROCHLORIDE) : 450 MG |
| Market authorization holder | CHEPLAPHARM ARZNEIMITTEL GMBH |
| Health Canada schedule | Prescription |
| ATC code | J05AB14 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J05AB |
| Current status | MARKETED |
| Status date | 19-Jul-2022 |
| Original market date | 2002-07-16 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
6 of 9 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-VALGANCICLOVIR | 50 MG | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | 02535483 |
| AURO-VALGANCICLOVIR | 450 MG | TABLET | AURO PHARMA INC | MARKETED | 02435179 |
| MINT-VALGANCICLOVIR | 450 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | 02495457 |
| TEVA-VALGANCICLOVIR | 450 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02413825 |
| VALCYTE | 50 MG | POWDER FOR SOLUTION | CHEPLAPHARM ARZNEIMITTEL GMBH | MARKETED | 02306085 |
| APO-VALGANCICLOVIR | 450 MG | TABLET | APOTEX INC | DORMANT | 02393824 |
| MYLAN-VALGANCICLOVIR | 450 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED PRE MARKET | 02426579 |
| NAT-VALGANCICLOVIR | 450 MG | TABLET | NATCO PHARMA (CANADA) INC | CANCELLED PRE MARKET | 02465744 |
2 · Same class — other molecules in ATC J05AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Valaciclovir | AG-VALACYCLOVIR · APO-VALACYCLOVIR · AURO-VALACYCLOVIR · BIO-VALACYCLOVIR · +17 more | 36 | 22 | Yes |
| Acyclovir | ACYCLOVIR · ACYCLOVIR SODIUM FOR INJECTION · ACYCLOVIR SODIUM INJECTION · ACYCLOVIR-200 · +17 more | 48 | 15 | Yes |
| Famciclovir | ACT FAMCICLOVIR · APO-FAMCICLOVIR · AURO-FAMCICLOVIR · AVA-FAMCICLOVIR · +7 more | 36 | 6 | Yes |
| Valganciclovir | APO-VALGANCICLOVIR · AURO-VALGANCICLOVIR · MINT-VALGANCICLOVIR · MYLAN-VALGANCICLOVIR · +3 more | 9 | 6 | Yes |
| Ganciclovir | CYTOVENE · CYTOVENE - CAP 250MG · CYTOVENE INJ 500MG/VIAL · CYTOVENE, 500 MG · +2 more | 9 | 4 | Yes |
| Remdesivir | VEKLURY | 2 | 1 | Yes |
| Cidofovir | MAR-CIDOFOVIR | 1 | 1 | Yes |
| Brincidofovir | TEMBEXA | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J05AR | Antivirals For Treatment Of Hiv Infections, Combinations · Atanazavir And Cobicistat · Darunavir And Cobicistat · Dolutegravir And Rilpivirine · Emtricitabine And Tenofovir Alafenamide · +16 more | 56 | 39 |
| J05AF | Abacavir · Adefovir Dipivoxil · Didanosine · Emtricitabine · Entecavir · +7 more | 71 | 39 |
| J05AH | Neuraminidase Inhibitors · Oseltamivir · Zanamivir | 33 | 16 |
| J05AX | Baloxavir Marboxil · Bulevirtide · Enfuvirtide · Fostemsavir · Inosine Pranobex · +5 more | 19 | 14 |
| J05AE | Amprenavir · Atazanavir · Darunavir · Fosamprenavir · Indinavir · +5 more | 75 | 14 |
| J05AG | Delavirdine · Doravirine · Efavirenz · Etravirine · Nevirapine · +1 more | 22 | 10 |
| J05AJ | Cabotegravir · Dolutegravir · Elvitegravir · Raltegravir | 12 | 6 |
| J05AP | Asunaprevir · Boceprevir · Daclatasvir · Dasabuvir, Ombitasvir, Paritaprevir And Ritonavir · Elbasvir And Grazoprevir · +8 more | 22 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is VALCYTE called?
The same molecule, Valganciclovir, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Valganciclovir Sandoz | Latin | Australia |
| Valganciclovir Viatris | Latin | Australia |
| BLUEVAL | Latin | Bahrain |
| Cytameg | Latin | South Africa |
| VALGAN | Latin | Saudi Arabia |
| valganciclovir | Latin | Saudi Arabia |
| Valgaset | Latin | Saudi Arabia |
| Valgiver | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.